Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with an $86.25 million public offering of common stock of Forty Seven, including the full exercise by the underwriters of their option to purchase additional shares of common stock. Forty Seven’s common stock is listed on The Nasdaq Global Select Market under the symbol “FTSV.”

Forty Seven is a clinical stage immuno-oncology company focused on developing novel checkpoint therapies to activate macrophages in the fight against cancer. Forty Seven is based in Menlo Park, California.

The Davis Polk corporate team included partner Sarah K. Solum and associates Bryan M. Quinn and Katherine Schloss Ackerman. Partner Rachel D. Kleinberg provided tax advice. Partner David R. Bauer and associate Jay Frankel provided intellectual property and technology advice. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post